



Life Sciences

INDUSTRY GROUP

Pharmaceutical & Animal Health
Biotechnology | Medical Devices



WOMBLE
CARLYLE [®]
INNOVATORS AT LAW[®]

Life Sciences Value Proposition

Womble Carlyle's Client Service Program keeps us in touch with in-house counsel at life sciences companies. Their priorities have become the "4 Cs" of our value proposition for pharmaceutical, animal health, biotechnology and medical device companies. Our life sciences lawyers deliver legal and business solutions with:

COMPETENCE: We stay current with the goals of your company, the science underlying your products and the issues facing your segment of the life sciences industry.

CARING: We care about how our services affect your long-term success—and plan and execute legal actions efficiently to meet strategic and financial goals.

COMMITMENT: We're dedicated to doing whatever it takes to ensure you get the timely advice and responsive support you need.

COMMUNICATION: We learn quickly how you prefer us to communicate, and we're diligent in letting you know where things stand and what we're doing throughout the legal process.

www.wcsr.com/lifesciences



OUR SERVICES HELP DRIVE CLIENT REVENUE

Our Life Sciences Industry Group has been guided by the challenges our life sciences clients face in the highly regulated and competitive marketplace. We believe this approach differs fundamentally from the traditional, internally focused thinking employed by most law firms. In our experience with pharmaceutical, animal health, biotechnology and medical device companies, we have observed that all segments have one thing in common: the never-ending challenge of creating successful, safe, cost-effective and regulatory-compliant products that provide the critical revenue streams that are the lifeblood of all successful life science companies—revenue streams that, once created, must be maintained and defended. The flow chart below is a representation of that Life Cycle Model.

FUNDING >>>

Collective Therapeutics: Assisted in finding and closing a \$27 million Series A financing to develop antibodies to treat cancer and autoimmune disorders.

Venture Capital Funds: Guided the formation and portfolio investments of more than 50 funds of all types, many of them in the life sciences space.

RESEARCH & DEVELOPMENT >>>

Targacept: Negotiated research/development agreements with large pharmaceutical companies and helped structure a \$45 million IPO to provide capital to develop drugs to combat central nervous system disorders.

Wake Forest University: Negotiated and drafted license agreements and sponsored-research agreements.

CLINICAL TRIALS >>>

Novartis: Successfully defended individual and class action lawsuits with claims totaling hundreds of millions of dollars arising from nationally publicized clinical trials investigations.

Genentech: Successfully defended cutting edge claims involving protocol design, ethics of placebo arm trials and standard of care owed to study subjects.

GOING TO MARKET >>>

Innogenetics N.V.: Negotiated and prepared license and distribution agreements for diagnostic and therapeutic products to defeat common diseases.

TriPath: Currently representing in litigation against Cytoc Corporation regarding patents for a process for reviewing and analyzing cervical slides.

NEW REVENUE STREAM ONLINE >>>

Bayer CropScience: Disqualified a class action involving claims of price-fixing.

Schering-Plough: Resounding victory (directed verdict) in complex suits involving allegations of monopoly, fraud, trade dress infringement and other claims.

REVENUE STREAM MATURES

GlaxoSmithKline: Favorable resolution of disputes with managed-care companies, business-line acquirers and vendors involving trade practices, breach of contract and trade-secret protection.

CONTACTS

Group Leader

Howard Grubbs
(864) 255-5413
hgrubbs@wcsr.com

Litigation

Robert E. Fields, III
(919) 755-2183
rfields@wcsr.com

Pressly M. Millen

(919) 755-2135
pmillen@wcsr.com

Intellectual Property

Carl B. Massey, Jr.
(336) 721-3681
cmassey@wcsr.com

Corporate and Securities

Jeffrey C. Howland
(336) 721-3516
jhowland@wcsr.com

Regulatory Compliance

Richard H. Vincent
(404) 879-2422
dvincent@wcsr.com

Womble by the Numbers

500+ LAWYERS

11 OFFICES IN 6 STATES AND WASHINGTON, D.C.

35 LAWYERS NAMED BEST IN FIELD BY CHAMBERS USA 2009

102 LAWYERS SELECTED FOR 2009 BEST LAWYERS IN AMERICA

Womble Carlyle is a full-service business law firm that provides a wide range of legal services that life sciences companies need in order to be successful. 330 of our lawyers—including a number of M.S. and Ph.D. level scientists—have served our life sciences clients. Our clients cover the continuum from venture capital-backed start-ups to Fortune 100 multi-national corporations.

Proving Grounds of Innovation

Northern Virginia/DC/Maryland

Research Triangle Park

Atlanta



Life Sciences

LITIGATION

- Product liability litigation
- Patent litigation
- Business litigation
- Clinical trial litigation
- National, statewide or local class actions
- Arbitrations or mediations
- Automated case management and reporting for mass tort litigation

INTELLECTUAL PROPERTY

- Procurement of U.S. and foreign patents
- Trademark and copyright registrations
- Patent investigations and analyses
- Opinions on patentability, infringement and permissive design around
- State-of-the-art and due diligence studies
- Enforcement of all IP rights, including trade dress protection

CORPORATE AND SECURITIES

- Technology transfers
- Venture capital financings
- Corporate partnerships
- Strategic research, development and commercialization arrangements
- Out-licensing and in-licensing agreements
- Clinical trials agreements
- Private placement
- Initial and follow-on public offerings
- Corporate spin-offs
- Mergers and acquisitions

REGULATORY COMPLIANCE

- Antitrust and trade regulation approvals
- Litigation involving federal and state antitrust laws, unfair and deceptive trade practices
- Business torts
- Advertising laws and regulations
- Unfair competition laws and trade libel strategies to manage regulatory impact
- Compliance programs

WWW.WCSR.COM/LIFESCIENCES